Tokai plans for Phase III trial of galeterone in 2015

Tokai Pharmaceuticals — a US-based biotechnology company — went public yesterday and was supposedly able to raise more than enough money to initiate a pivotal, Phase III, randomized clinical trial of its investigational drug galeterone (TOK-001) in treatment of late stage prostate cancer. … READ MORE …

FDA approves use of enzalutamide in chemotherapy-naive mCRPC

This afternoon the U.S. Food & Drug Administration approved enzalutamide (Xtandi) as a treatment for patients with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) based on the results of the PREVAIL trial. … READ MORE …

ASCO, CCO issue new guidelines for management of metastatic prostate cancer

The American Society for Clinical Oncology (ASCO), in conjunction with Cancer Care Ontario (CCO), has just issued revised guidelines for the management of metastatic prostate cancer. … READ MORE …

DCVAC/PCa and the VIABLE trial in men with mCRPC

It has been brought to our attention that a Czech company called Sotio, based in Prague, has recently initiated a randomized, multi-center, Phase III clinical trial (known as the VIABLE trial) of what appears to be a “second-generation” form of activated dendritic cell-based immunotherapy for the treatment of advanced prostate cancer. … READ MORE …

Cabozantinib shows no survival benefit in COMET-1 trial

Exelixis has announced that the COMET-1 trial of cabozantinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) has failed to show a statistically significant survival benefit. The company has also stopped enrollment into the COMET-2 trial. … READ MORE …

Living with late stage prostate cancer

There is a valuable video interview that was put on line a couple of days ago featuring Dr. William Oh of the Mount Sinai Hospital and Medical School in New York and Jan Manarite of the Prostate Cancer Research Institute. … READ MORE …

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers